Moreover, WK2-16 effectively synergizes with quizartinib (AC220), a second-generation TKI [136], in FLT3-ITD+ AML to exhibit anti-leukemia effects in vitro and in vivo. This evidence concerns the gene FLT3 and acute myeloid leukemia.